Genmab — April 2017

[gentogen]

2644 / 3 - SY-1425, a selective RARα agonist, induces high levels of CD38 expression in RARA-high AML tumors creating a susceptibility to anti-CD38 therapeutic antibody treatment

[gentogen]

By inducing the expression of CD38, SY-1425 in combination with DARA elicits tumor cell death and NK cell activation. Based on these findings, a phase 2 clinical study with SY-1425 in combination with an anti-CD38 antibody is planned in AML using an RARA biomarker patient selection strategy.

[gentogen]

Program Planner

(www.abstractsonline.com)

[gentogen]

The combination of SY-1425 and DARA led to a six-fold increase in tumor cell death relative to the single agent controls, and 5-10 fold increases in NK cell activation is observed only in the SY-1425 and DARA combination treatment of RARA-high AML cell lines.

[Bulder]

Hold da op. Du har haft travlt gentogen. Så hvad har vi nu? Et præklininsk studie, der påpeger synergi mellem dara og CS1-CAR NK celler i MM. Og dara mono i T-ALL. Et fase 1 studie er planlagt. Samt en kombination af SY-1425 og dara i AML. Et fase 2 studie er planlagt.

[E_L]

good find again. we discussed the middle one, SY-1425, on the back of a Yahoo article last week, i think Thursday. It must be this study that they will expand to include Dara: https://clinicaltrials.gov/ct2/show/NCT02807558?term=NCT02807558&rank=1

[E_L]

I could imagine Syros would want to
present this at ASCO also

[Mcjean]

It should pop up on CCN soon;-)

[Mcjean]

i wonder how good six-fold is and 5-10 fold increases in NK cell?

[E_L]

Is that new, the Cable Copenhagen Network ?

[Mcjean]

1-0

[royal]

Juve

[Bulder]

Alcyone er opdateret 7/4. Antallet af lokationer er - siden januar - udvidet fra 179 til 209. Ud af de 209 lokationer er 29 "completed". Ud af 12 US-lokationer er 7 "completed". https://www.clinicaltrials.gov/ct2/show/study/NCT02195479?term=daratumumab+and+velcade&rank=1&show_locs=Y#locn

[KWC]

Tak Gento for update..

[bibob]

God morgen.

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

With an estimated enrolment of 700 patients for Alcyone, that would only be 3-4 patients per location. Do you think enrolment will stop when 700ish is reached or does each location need to make its minimum?

[Bulder]

Jeg ved ikke hvad det betyder. Det er jo længe siden, at genmab annoncerede at studiet var fuldt rekrutteret. Jeg troede, at de derved havde nået de 700 pts. Men de fleste lokationer rekrutterer stadig på livet løs. Det undrer mig også at de udvider med 30 lokationer uden at samlet antal pts øges.

[DevOp]

Der indsamles interim efficacy results i Alcyone efter ca. 216 PFS events - gad vide, om Janssen har tænkt sig at offentliggøre dem inden endelig indsamling af efficacy data 1.nov.